{
    "symbol": "CRIS",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-05 04:42:06",
    "content": " For the second quarter of 2022, Curis reported a net loss of $15.9 million or $0.17 per share on both a basic and diluted basis, as compared to a net loss of $10.8 million or $0.12 per share on both a basic and diluted basis for the same period in 2021. For the six months ended June 30, 2022, we reported a net loss of $32 million or $0.35 per share, as compared to a net loss of $20.8 million or $0.23 per share for the same period in 2021. Revenues for the six months ended June 30, 2022 and June 30, 2021 were $4.5 million. Operating expenses for the second quarter of 2022 were $17.5 million, as compared to $12.9 million for the same period 2021. Operating expenses for the six months ended June 30, 2022 were $34.6 million, as compared to $23.9 million for the same period 2021 and comprised the following: cost of royalty revenues, which comprised amounts due to third-party university patent licensors in connection with Genentech and Roche's Erivedge net sales were less than $0.1 million for the second quarter of 2022, as compared to $0.1 million for the same period in 2021. Positive royalty revenues for the six months ended June 30, 2022 were $0.1 million, as compared to $0.2 million for the same period 2021. Research and development expenses were $12.3 million for the second quarter of 2022, as compared to $8.8 million for the same period in 2021. Research and development expenses were $23.8 million for the six months ended June 30, 2022, as compared to $15.5 million for the same period 2021. General and administrative expenses were $5.1 million for the second quarter ended June 30, 2022, as compared to $4.1 million for the same period in 2021. General and administrative expenses were $10.8 million for the six months ended June 30, 2022, as compared to $8.2 million for the same period in 2021. Total other expense was $1.9 million for the six months ended June 30, 2022, as compared to $1.3 million for the same period in 2021."
}